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Non-antibody scaffold proteins are used for a range of
applications, especially the assessment of protein–protein
interactions within human cells. The search for a versatile,
robust and biologically neutral scaffold previously led us
to design STM (steﬁn A triple mutant), a scaffold derived
from the intracellular protease inhibitor steﬁn A. Here, we
describe ﬁve new STM-based scaffold proteins that
contain modiﬁcations designed to further improve the ver-
satility of our scaffold. In a step-by-step approach, we
introduced restriction sites in the STM open reading
frame that generated new peptide insertion sites in loop 1,
loop 2 and the N-terminus of the scaffold protein. A
second restriction site in ‘loop 2’ allows substitution of the
native loop 2 sequence with alternative oligopeptides.
None of the amino acid changes interfered signiﬁcantly
with the folding of the STM variants as assessed by circu-
lar dichroism spectroscopy. Of the ﬁve scaffold variants
tested, one (steﬁn A quadruple mutant, SQM) was chosen
as a versatile, stable scaffold. The insertion of epitope tags
at varying positions showed that inserts into loop 1,
attempted here for the ﬁrst time, were generally well toler-
ated. However, N-terminal insertions of epitope tags in
SQM had a detrimental effect on protein expression.
Keywords: circular dichroism spectroscopy/epitope
recognition/peptide aptamer/scaffold protein
Introduction
Although antibodies have proven to be useful tools in a
broad range of applications, they also possess some inherent
limitations. Owing to their complex structure and extensive
glycosylation, antibodies are fragile molecules with low
yields in bacterial expression systems, having a high temp-
erature sensitivity, and expensive production costs. Their
correct folding relies on the formation of intramolecular dis-
ulphide bonds and as a consequence they frequently do not
function in the reducing environment inside eukaryotic cells
(Skerra, 2007). Furthermore, it is often very challenging or
impossible to raise antibodies that are able to distinguish
between different isoforms or mutants of proteins, an often
wished for tool in clinical diagnostics.
It is therefore not surprising that for more than 14 years a
great deal of effort has been invested in the design of non-
antibody scaffold proteins that can present recognition sur-
faces that expand the immune repertoire. This has resulted in
the description of over 40 artiﬁcial proteins that have been
engineered to present peptides as recognition moieties
(reviewed in Binz et al., 2005). Major classes of engineered
scaffolds include those based on folds from proteins as
diverse as protein Z (Afﬁbodies, Nord et al., 1995),ﬁbronectin
(Adnexins, Koide et al., 1998), ankyrin repeat proteins
(DARPins, Binz et al., 2003; Kohl et al., 2003), cysteine-knot
miniproteins (Knottins, Clark et al., 2006; Kolmar, 2008) or
Armadillo repeat proteins (Parmeggiani et al., 2008), as well
as on full-length proteins such as lipocalins (Anticalins,
Schlehuber and Skerra, 2005), ColE7 immunity protein (Im7,
Juraja et al., 2006), the green ﬂuorescent protein GFP (Abedi
et al., 1998) and thioredoxin A (LaVallie et al., 1993). A
major rationale of this work has been that conformational con-
straints enforced on inserted peptides by the scaffold protein
will decrease the entropic cost of binding and lead to
increased binding afﬁnities (Ladner, 1995). A second motiv-
ation has been the idea that whereas free peptides are readily
degraded by cellular proteases, full-length folded proteins are
expected to be more stable (Saveanu et al., 2002; Reits et al.,
2003). Similarly, antibodies that have evolved to function in
the extracellular environment function poorly within eukary-
otic cells. These considerations led Colas et al. to establish a
yeast two-hybrid screening system to identify conformation-
ally constrained peptides that would bind to target proteins
within the intracellular environment of a eukaryotic (yeast)
cell, coining the term ‘peptide aptamer’ to describe such tools
(Colas et al., 1996; Colas, 2008). In addition to their ability to
function inside cells, peptide aptamers possess several attri-
butes in common with other constrained peptides that dis-
tinguish them from antibodies, including small size (typically
10–15 kDa, compared with 150 kDa for IgG), lack of post-
translational modiﬁcation (IgG requires extensive glycosyla-
tion of the constant region for stability) and being comprised
of a single polypeptide chain (IgG is comprised of two copies
each of a heavy and a light polypeptide chain). Nonetheless,
peptide aptamers posses binding afﬁnities that are comparable
to most antibodies, in the pM–nM range (Cohen et al., 1998).
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bacterial expression systems, increased thermal and chemical
stability as well as the ability to functionally fuse with reporter
proteins (Kolmar and Skerra, 2008).
A major concern with any approach is that the introduction
of a scaffold protein itself into cells may lead to phenotypes
that may complicate or mask the effects of the displayed
peptide. For example, thioredoxin was chosen because the
use of a bacterial protein scaffold was thought unlikely to
produce interactions with proteins in human cells. However,
expression of bacterial thioredoxin protein is anti-apoptotic
and is able to decrease ischemia in mouse models (Tao
et al., 2004).
Accordingly, we have sought to produce a new scaffold
for the presentation of constrained peptides that would be
‘biologically neutral’, i.e. would not interact with human pro-
teins. After an initial investigation of several candidates, we
found that human steﬁn A (SteA, also called cystatin A)
could be engineered to possess all of the desirable character-
istics (Woodman et al., 2005). Steﬁn A is a small (98 amino
acid) monomeric protein inhibitor of the cystatin family I
(steﬁns) that inhibits cysteine proteases of the cathepsin
family (Turk et al., 1986). It interacts with its partner pro-
teins, cathepsins B, C, H, L and S (Brzin et al., 1984; Green
et al., 1984; Abrahamson et al., 1986) using three sites, with
key contacts made by glycine at position 4, valine at position
48 and lysine at position 73 (Bode et al., 1988; Stubbs et al.,
1990; Martin et al., 1994, 1995; Tate et al., 1995; Pavlova
and Bjo ¨rk, 2002; Jenko et al., 2003). Biological neutrality
was achieved through a combination of two rational
mutations [G4W to abolish interaction with cathepsins
(Estrada et al., 1998, 1999) and V48D to abolish interaction
with cathepsins and reduce dimer formation through domain
swapping (Japelj et al., 2004)] and a third mutation to intro-
duce a unique RsrII restriction site at codons 71–73, which
becomes the insertion site for oligonucleotides encoding
short peptides. The use of this site allowed us to introduce
peptides into the longest loop found in SteA, known as loop
2 (Bode et al., 1988; Stubbs et al., 1990; Martin et al., 1994,
1995; Tate et al., 1995; Pavlova and Bjo ¨rk, 2002). The engin-
eered protein was designated STM, for steﬁn A triple mutant
(Woodman et al., 2005).
However, despite the success of this scaffold in presenting
certain peptides for interaction (Woodman et al., 2005;
Estrela et al., 2008; Evans et al., 2008; Johnson et al., 2008;
Shu et al., 2008; Davis et al., 2009), there was clear room for
further improvement. Most importantly in our view, crystal
structures of steﬁn A in complex with its target cathepsin
revealed that the parental SteA protein uses three non-
contiguous peptide surfaces, comprising the amino terminus,
loop 1 and loop 2, to interact with its target (Bode et al.,
1988; Stubbs et al., 1990; Martin et al., 1994, 1995; Tate
et al., 1995; Pavlova and Bjo ¨rk, 2002; Jenko et al., 2003).
We wished to make use of the whole of this ‘tripartite
wedge’ for interaction with targets, so as to maximize both
binding afﬁnity and the speciﬁcity of interaction.
The goal of the present study is to assess the effect on the
SteA protein of introducing step-by-step amino acid changes
at speciﬁc locations, alone and in combination, that would
result from the generation of restriction sites in the open
reading frame to be used for oligonucleotide insertion.
Having identiﬁed a number of potential changes that do not
adversely affect the folding of the engineered protein as
assessed by circular dichroism (CD) spectroscopy, we asked
whether a series of model peptides could be presented by the
newly engineered scaffold protein, a steﬁn A quadruple
mutant (SQM). We found (i) that inserts into the amino
terminal region that mediates most of the protein contacts in
SteA co-crystals frequently disturb the secondary structure of
the protein, as analysed by CD spectroscopy and protein
expression yields in E.coli; (ii) that replacement of loop 2 in
SQM may adversely affect protein yields compared with the
longer inserts that result from insertion into loop 2 in STM;
and most surprisingly (iii) that short inserts into both loops 1
and 2 simultaneously can increase the apparent stability of
the protein. Together, these data suggest new ways of
working with steﬁn A derived scaffold proteins and may
shed light on determinants of folding and stability of the
steﬁn A protein itself.
Materials and methods
Plasmids and DNA manipulation
pET30a(þ), for the expression of His6-tagged proteins in
bacteria, was purchased from Novagen (Nottingham, UK).
The SteA variant STM in pET30a(þ) was used as published
(Woodman et al., 2005). DNA manipulations followed stan-
dard protocols (Sambrook and Russell, 2001), using enzymes
obtained from NEB (MA, USA). Oligonucleotides were from
Invitrogen (Paisley, UK) and are listed in Supplementary
Table B (Supplementary data are available at PEDS online).
The genes encoding the STM variants SDM (steﬁn A double
mutant), SQM, SUM (steﬁn A unique middle), SUN (steﬁn
A unique N-terminus) and SUC (steﬁn A unique C-terminus)
were synthesized and cloned into pET30a(þ) by Genscript
(Piscataway, NJ, USA). Site-directed mutagenesis was per-
formed according to Fisher and Pei (1997). All DNA manip-
ulations were conﬁrmed by sequencing.
Insertion of peptides into the SteA-based scaffolds
Double-stranded oligonucleotide cassettes ﬂanked by
required restriction site overhangs and encoding a peptide tag
(Supplementary Table A, Supplementary data are available
at PEDS online) were made by annealing oligonucleotides
(Supplementary Table B, Supplementary data are available at
PEDS online). Digested dsDNA cassettes were ligated into
the appropriate restriction sites of the scaffold-encoding open
reading frame in pET30a(þ).
Production of STM variant recombinant proteins in E.coli
pET30a(þ) STM variants were transformed into the E.coli
strain BL21 (DE3, Novagen, USA) that provides increased
protein stability due to its Ion and OmpT deﬁciency (Shaw
and Ingraham, 1967). The cells were grown to A600 ¼ 0.6 in
Luria–Bertani broth (Sambrook and Russell, 2001) at 378C,
and protein expression was induced with 0.4 mM IPTG.
After 3 more hours of growth, the cells were harvested and
resuspended in protein lysis buffer [50 mM Na2HPO4/
NaH2PO4, 300 mM NaCl, supplemented with a complete
protease inhibitor mix lacking EDTA (Roche)]. The cells
were lysed using a cell disrupter (Constant Systems,
Northants, UK). The His6-tagged proteins were captured on
Ni-NTA columns (Qiagen) and, after extensive washing of
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with 30 mM imidazole, eluted with 250 mM imidazole into a
50 mM sodium phosphate, 300 mM NaCl buffer.
Far-UV CD spectroscopy
Puriﬁed proteins were transferred into 50 mM sodium phos-
phate (pH 7.4) using buffer exchange columns (Amicon Ultra
10 kDa, Millipore), and their concentrations determined by
measuring the absorbance at 280 nm (NanoDrop ND-8000,
Thermo Scientiﬁc). CD spectra were recorded on a Jasco J715
spectropolarimeter at 108C using a 300-ml quartz cuvette with
d ¼ 0.1 cm path length. Folding spectra were collected from
190 to 260 nm. The raw output is given in ellipticity [u
(mdeg)]. The data were normalized by calculating the mean
residue ellipticity u using the following equation:
½u l ¼
u   100   Mr
c   d   n
ð1Þ
where [u]l is the mean residue ellipticity (deg   cm
2  
dmol
21), u the observed ellipticity (in mdeg) at wavelength l
(in nm), Mr the molecular weight of the peptide (in g/mol),
c the concentration (in mg/ml), d the path length (in cm) and
n the number of residues. Three to eight spectra were taken
for each STM variant and averaged, and the average spectrum
for the buffer alone was subtracted to produce the ﬁnal curves.
The data were analysed using Microsoft
w Excel
w (version
12.5.1 for Mac OS) and visualized using Plot (version 0.997,
Michael Wesemann, http://plot.micw.eu/).
Immunoprecipitation
Myc-tagged SQM peptide aptamers were immuno-
precipitated using anti-Myc tag antibody-coated agarose
resin (Abcam). About 10 ml of the resin was blocked in
250 ml of 50 mM sodium phosphate (pH 7.4) with 4%
bovine serum albumin (BSA) and 0.1% Nonidet P-40
(NP-40, Calbiochem) for 1 h at 48C. The resin was then
washed three times in wash buffer (50 mM sodium phosphate
with 0.05% BSA and 0.1% NP-40). Subsequently, the resin
was incubated with 2 mg of puriﬁed peptide aptamer dis-
solved in 200 ml of WB for 2 h at 48C, followed by seven
washes in 200 ml WB. Protein sample buffer was added
(Laemmli, 1970), the sample boiled for 5 min and analysed
by SDS–polyacrylamide gel electrophoresis followed by
western blotting with anti-S-tag monoclonal antibody
(Novagen) targeting the S-tag added by the pET30a(þ)
vector to the amino-terminus of the peptide aptamer.
Microarray experiments
Microarray assays were performed with antibodies (Ab9106
Myc-tag polyclonal, Ab16 918 HA tag monoclonal and
Ab24620 AU1 tag monoclonal, from Abcam) labelled 1:1
with Atto dyes (Atto 550-NHS ester and Atto 647N-NHS
ester). Labelling was conﬁrmed via a Nanodrop spectropho-
tometer. All samples have been spotted (BioOdessy, Biorad
Corp.) on nickel NTA histag afﬁnity (Xenopore Corp) sur-
faces using 100 mm capillary pins. Samples were printed at
concentrations of 10 mM in print buffer, which comprised of
PBST and 10% glycerol. Sample arrays were printed in
repeats of four and the entire array was repeated three times
across the slide. Spotted volumes were allowed to incubate
on the slide for 60 min, prior to a blocking step in 1% BSA
PBST for 60 min. Labelled antibodies were incubated at con-
centrations of 7–28 nM in 1% BSA PBST for 40 min using
50 ml volume Lifterslips (Thermo Scientiﬁc). Slides were
washed in PBST twice for 10 min then twice in deionized
water for 2 min. The slides were dried under a stream of
nitrogen and scanned at a resolution of 5 mm with 543 and
633 nm lasers under the Cy3 and Cy5 detection protocol
(Scan Array Express, Perkin Elmer).
Results
Although STM can be used to present peptide aptamers
that interfere with biological processes (J.T-H. Yeh, R.
Woodman, and P. Ko Ferrigno, unpublished), we found that
screens of random peptide libraries created by insertion into
loop 2 frequently led to the identiﬁcation of truncated
peptide aptamers. These were produced by oligonucleotides
that encoded either in-frame or out-of-frame stop codons,
leading to the loss of the C-terminal 23 residues of steﬁn A
(Woodman et al., 2005). We reasoned that the selection of
these ‘unconstrained’ peptides from libraries may result from
an inability of the scaffold to tolerate or correctly present a
wide range of peptide sequences inserted into loop 2. To cir-
cumvent this problem and to increase the available surface
area used for interaction with targets, we set out to further
engineer the scaffold protein.
Generation of SteA mutants and selection of an improved
scaffold protein
We set out to improve the STM scaffold, shown schemati-
cally in Fig. 1A. We used a step-by-step approach introdu-
cing successive mutations into the steﬁn A gene to generate
new insertion sites for oligonucleotides because it was
unknown whether any of the planned modiﬁcations would be
tolerated by the encoded protein. In doing so, we were able
to examine the effect of single amino acids changes at differ-
ent positions, as well as the effects of those changes in com-
bination with others. First, we introduced mutations at
unique sites in the wild-type steﬁn A gene.
These engineered proteins were designated SUN (encoded
by the SteA open reading frame possessing an AvrII site at
codon 4) and SUM (with an NheI site at codons 48–50
inclusive). Second, a double mutant was generated, desig-
nated SUC (two RsrII sites in codons 71–73 and 82–83
inclusive). Third, a triple mutant designed to allow insertions
into loops 1 and 2 was designated SDM (with NheIa t
codons 48–50 and two RsrII sites at codons 71–73 and 82–
83). Finally, we conceived a quadruple mutant, SQM that
combines all of these changes in one open reading frame.
The corresponding changes in the amino acid sequences are
shown in Fig. 1B. SQM represents a version of the desired
ﬁnal scaffold including all modiﬁcations that would allow
the insertion of short random peptides into the N-terminus
and loop 1 as well as the replacement of loop 2. This combi-
nation is designed to provide a high versatility and binding
afﬁnity.
We used two methods to determine the effect of the amino
acid changes on the scaffold structure. The ﬁrst method is
simply to determine the relative expression levels of the
engineered proteins in E.coli, with the rationale that most
amino acid changes are likely to destabilize the protein and
decrease yields of soluble protein. The second method is to
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protein isoform by CD spectroscopy.
When comparing protein yields from E.coli, we measured
the amount of puriﬁed steﬁn A variant that could be recov-
ered on Ni-NTA afﬁnity columns of a given volume and
standardized this number to the volume of starting culture.
We found that each individual change from steﬁn A either
had little effect on normalized yields or occasionally led to
increased yield compared with STM. Thus, in ﬁve prep-
arations of STM, the average yield was 46+16 mg of puri-
ﬁed STM from 1 l of culture, whereas for SUN the average
yield was 42+14 mg/l of culture (n ¼ 3), SUM 31+8 mg/l
of culture (n ¼ 3) and SUC 53+9 mg/l of culture (n ¼ 3).
This was true also when we combined two mutations in one
protein, as the yield for SDM was 46+7 mg/l of culture.
When we made changes at all three sites simultaneously in
SQM, the yield was 49+11 mg of puriﬁed protein per litre
of culture (average of seven preparations).
CD spectroscopy allows an assessment of secondary struc-
ture elements (a-helix and b-sheet) present in a given
protein, but can neither readily distinguish between the two
nor can CD spectroscopy be used to predict secondary struc-
ture ab initio. However, we believe CD spectroscopy to be a
useful tool for determining whether or not amino acid altera-
tions or peptide insertions have perturbed the secondary
structure of the well-characterized steﬁn A protein as mul-
tiple spectra for the parental protein are available (Turk
et al., 1983; Zerovnik et al., 1991; Pol et al., 1995; Jerala and
Zerovnik, 1999; Kenig et al., 2001). In using CD spec-
troscopy, we wish simply to ask whether the proportion of
secondary structure remains constant following each engin-
eering step. A change in the shape of the CD spectrum plot
would reﬂect changes in the a-helical and b-sheet content of
the folded protein. CD spectra for the different STM variants
were obtained between 200 and 260 nm STM (Fig. 2). All
STM variants showed similar CD spectra with an inﬂexion
point at around 219 nm. The CD spectrum of STM appears
to be slightly shifted towards the far UV compared with
other variants. However, we also observed differences in the
amplitude of the CD spectra with SQM, SUM and SUN
showing a deeper curve compared with STM (Fig. 2; see
Discussion).
SQM presents peptides in loop 2 differently than STM
In generating SQM from STM, an additional RsrII site was
introduced into the loop 2 encoding region of the STM open
reading frame. As a consequence, the leucine at position 82
and threonine at 83 were changed to arginine and serine,
respectively. The two RsrII sites allow the substitution of the
native ‘loop 2’ sequence with a random oligopeptide. This
was expected to be less disruptive compared with STM
where the use of a single insertion site inevitably extends
loop 2, but may also affect the way that peptide inserts are
presented.
Different oligonucleotides were inserted into each open
reading frame so as to present encoded peptides at loop 2 of
both the STM and SQM scaffolds. Initially, we inserted oli-
gonucleotides that encode short peptides (A48, A52 and A58,
each 10 amino acids long; and A7: 17 amino acid long;
Supplementary Table A, Supplementary data are available at
Fig. 1. Engineering novel scaffolds from steﬁn A. (A) Schematic representation of the structure of the engineered SQM protein. A three-dimensional
representation of the SQM protein, using the SWISS-MODEL modelling service (Guex and Peitsch, 1997; Schwede et al., 2003; Arnold et al., 2006) using the
steﬁn A structure as a template (PDB ID: 1nb5k; Jenko et al., 2003). The data were visualized using MacPyMol v0.99 (http://pymol.org/). The a-helix is
coloured in red, b-sheets in blue and insertion sites in green. The surface that is potentially covered by inserts is shown in grey. (B) Sequence alignment of
steﬁn A-derived scaffold proteins. The amino acids are given in the single-letter code. The positions of the last residue in the alignments are listed in the
right-hand column. Secondary structures taken from the model are indicated below the alignment as a coil (a-helix), black arrows (b-sheets) and double lines
(loops). The restriction sites (AvrII, NheI, RsrII) we introduced into the open reading frame to allow the insertion of peptide-encoding oligonucleotides are
shown on the top and the resulting amino acid changes are shown in lower case. Note that all the steﬁn A variants used in this work are expressed as
HexaHistidine fusion proteins from the pET30a(þ) vector (Novagen) and include a 51 residue amino-terminal extension into which we have added a cysteine
residue at position 14, seven residues after the His tag, and a StrepII tag (Davis et al., 2007). This extension is not shown in this alignment. The alignment ﬁle
was produced using ClustalX (Thompson et al., 1997) and visualized by TEXshade (Beitz, 2000). The colour version of this ﬁgure is available at PEDS online.
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406PEDS online) that bind to the POZ domain of BCL-6 when
displayed by the thioredoxin A scaffold (Chattopadhyay
et al., 2006). In the course of cloning, concatamerization of
two oligonucleotides gave rise to a longer peptide, designated
A52tandem, comprising 22 amino acids. Expression levels of
these peptide aptamers in SQM were comparable to, or
slightly exceeded, the expression levels obtained when using
STM. Interestingly, one oligopeptide (A7) caused a deviation
from the reference CD spectra of ‘empty’ STM (Fig. 3A) but
not of empty SQM (Fig. 3B). The data are consistent with the
lower yield of STM-A7 (23 mg protein/l of culture) compared
with SQM-A7 (41 mg/l of culture) when expressed in E.coli
and indicate that, at least in the case of A7, SQM may present
peptides in loop 2 differently than STM.
We then turned to a model set of peptide inserts (pep2,
pep6, pep10m: 20 amino acids; pep9: 42 amino acids;
Supplementary Table A, Supplementary data are available at
PEDS online) that were initially identiﬁed by Colas et al.
(1996) as being able to bind to human CDK2 when presented
by the thioredoxin A scaffold. To our surprise, the yield of
protein from bacterial cultures was now lower when the pep-
tides were in SQM compared with STM (STM and SQM:
pep2, 19 and 9 mg/l; pep6, 36 and 2 mg/l; pep10m, 58 and
2 mg/l; pep9, 89 and 2 mg/l). Collected CD spectra for these
peptide aptamers also showed a decreased tolerance for
insertions in ‘loop 2’ of SQM than in STM (Fig. 3C and D).
These data conﬁrm that peptides in loop 2 of SQM behave
differently than peptides inserted in loop 2 of STM.
SQM can present peptide inserts for interaction
with target proteins
We wished to make a preliminary assessment of whether
SQM would be able to present peptides for interaction.
Accordingly, we turned to our previous strategy (Woodman
et al., 2005) of asking whether simple epitope tags would be
recognized by their cognate antibodies when presented in the
new sites created in SQM. We chose three peptide epitopes
(AU1, HA and Myc tags) that differ in both length and
physico-chemical characteristics (Supplementary Table A,
Supplementary data are available at PEDS online). These
peptides were inserted singly or in various combinations into
the positions we have designed in the SQM scaffold (the
N-terminus, loop 1 or loop 2). Initially, we inserted the HA
tag into the amino terminal site, the AU1 tag (the shortest
peptide) into loop 1 (the shortest loop) and the Myc tag into
loop 2. To our surprise, insertions of the HA tag into the
amino terminus were only poorly tolerated, with yields of
protein decreased more than 2.5-fold compared with the
empty scaffold [SQM-HA(N): 19 mg of puriﬁed protein/l of
culture, compared with SQM: 49+11 mg/l of culture).
Similarly, Myc insertion into loop 2 resulted in .5-fold
decrease in protein yield in E.coli. In contrast, insertion of
the AU1 tag into loop 1 did not destabilize SQM and may in
fact increase yields (Table I).
These adverse effects of peptide insertion could be due to
the insertion of ‘any’ peptide at each site, or to the insertion
of a peptide with a given sequence at that site. Accordingly,
we asked whether insertion of the Myc epitope peptide in the
amino terminal site had similar effects to the insertion of the
HA peptide. Myc insertion into the amino terminus also led
to a decrease in yield, especially when comparing SQM with
an AU1 tag in loop 1 to SQM with the Myc tag in the
N-terminal site combined with the AU1 tag in loop 1
(Table I). In addition, the combination of the N-terminal HA
insertion with any other in loop 1 or 2 resulted in lower
yields compared with similar peptide aptamers lacking the
Fig. 2. Far-UV CD spectra of different STM-based scaffold proteins. The far-UV CD spectra of several scaffold proteins that were designed based on the
STM scaffold are shown (STM, black line; SUN, dotted line; SUM, streak-double-dotted line; SUC, short streaked line; SDM, long streaked line; SQM,
streak-dotted line). The data are expressed as mean residual ellipticity (MRE, [u]). Vertical error bars indicate the standard deviation of ﬁve STM (red) or
seven SQM (blue) CD spectra obtained from independent sample preparations. The colour version of this ﬁgure is available at PEDS online.
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407HA inserts. Similarly, the Myc insertion at loop 2 was uni-
formly destabilizing of all other peptide aptamer variants.
The highest yield we obtained, over 200 mg of peptide
aptamer per litre of culture representing a 4-fold increase in
yield over the empty scaffold, involved SQM with insertions
of the AU1 tag at loop 1 and the HA tag at loop 2, with no
insertion into the amino terminus. We conclude that although
some peptides may be tolerated by the amino-terminus of
SQM, this will not be a generally useful site.
Analysis of peptide aptamer secondary structure
by CD spectroscopy
We next asked whether the insertion of the epitope tags into
the three sites as described above (Table I) affected the pro-
portion of secondary structure in the resulting peptide apta-
mers. To our surprise, even those insertions that decreased
protein yields did not appreciably disrupt the secondary
structure of the resulting peptide aptamers (Fig. 4A). We did
note that the presence of a peptide at the N-terminal site
changes the shape of the curve, pushing the inﬂexion point
from 218 towards 209 nm (Fig. 4B SQM-HA). In order to
ask whether this may reﬂect a general effect of insertions at
this site on the structure of the scaffold, we analysed the
spectra for a range of SQM-derived peptide aptamers with
inserts in loop 1 and/or loop 2, all with an insert at the
amino terminus. We consistently found the secondary struc-
ture of these proteins to be more disrupted, with inﬂexion
points at 209 nm, than the corresponding proteins lacking an
insert at the N-terminal site (Fig. 4B).
Speciﬁc recognition of peptide aptamers by antibodies
Having determined that it is possible, within limits, to insert
model peptides into each of the three positions, we wished to
ask whether the inserted peptides were presented to solvent
or were being incorporated into the secondary structure of an
aberrantly folded scaffold. In order to do this, we wanted to
know whether antibodies speciﬁc for each inserted epitope
could recognize their target in the scaffold. First, we asked
whether the AU1 peptide inserted into ‘loop 1’ could be
recognized by an anti-AU1 antibody. To this end, we asked
whether an anti-AU1 antibody could immuno-precipitate
model peptide aptamers presenting the AU1 epitope tag in
each site in turn. Indeed, the interaction was sufﬁciently tight
that each peptide aptamer could be immuno-precipitated
(data not shown). Next, we asked whether other epitope tags
would be equally well recognized. To this end, we used scaf-
fold proteins in which the Myc epitope peptide had been
inserted in either the amino terminus, loop 1 or loop 2. We
Fig. 3. Far-UV CD spectra of the STM scaffold protein compared with SQM containing short peptide insertions in loop 2. Shown are the far-UV CD spectra
of the STM (A and C) and SQM (B and D) scaffold proteins containing short peptide inserts [A and B: A7, A48, A52, A52tandem (tandem insertion of A52)
and A58; C and D: pep2, pep6, pep9 and pep10m) in loop 2 compared with a reference spectrum of the STM (red) or SQM (blue) scaffold. The data are
expressed as mean residual ellipticity (MRE, [u]). Vertical error bars indicate the standard deviation of ﬁve STM (red) or seven SQM (blue) CD spectra
obtained from independent sample preparations shown in Fig. 2. The colour version of this ﬁgure is available at PEDS online.
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anti-Myc antibody, to ask whether the peptide was displayed
on the surface of the folded protein, and used western blot-
ting to detect the scaffold protein. As before, the epitope tag
was equally well recognized regardless of the insertion site
and appeared not to be affected by insertions at other sites in
the same scaffold (Fig. 5).
Functionality of the SQM derivatives
Because of the combinatorial nature of the SQM scaffold
with three possible insertion sites, we have devised a micro-
array assay that allows us to look at many peptide aptamers
simultaneously using cognate antibodies of epitope tags
incorporated at several sites independently. Peptide aptamers
with various combinations of epitope inserts were spotted
and allowed to chelate onto glass slides coated with
nickel-NTA in order to induce oriented immobilization by
the His tag. Subsequently, surfaces were blocked using 1%
BSA PBST buffer and then incubated with the ﬂuorescently
labelled antibody at a concentration of 7 nM. After thorough
washing, the slides were scanned using a standard DNA
microarray scanner (Fig. 6). Tag-less aptamers and print
buffer control spots all gave the expected lack of signal.
Peptide aptamers containing the Myc and HA tags gave
strong signals. Peptide aptamer samples containing the AU1
tag consistently gave much weaker signals compared with
the Myc and HA counterparts, and on occasions could not be
seen. In order to increase AU1 signal strength, the antibody
incubation concentration was increased to 28 nM, which
resulted in identiﬁable spots. Since all our model peptide
aptamers were spotted at the same concentration of 10 mM,
the possibility of concentration variations correlated with
signal variation can be ruled out. Furthermore, internal con-
trols of samples containing all three tags, where by deﬁnition
the equimolar amounts of all three tags are present, showed
the same systematic signal variations. This issue was inde-
pendent of the insert position and is thus likely due to the
short size of the AU1 tag leading to a lower binding afﬁnity
by the anti-AU1 antibody (see Discussion).
We have also analysed the expression proﬁles of 384
random peptides inserted at each of the three sites (Fig. 7).
For this experiment, we grew small scale (1 ml) cultures of
E.coli expressing the random peptide aptamers in 96-well
plates, puriﬁed the peptide aptamers in high throughput (i.e.
without optimizing expression or puriﬁcation protocols for
each well) and spotted an equal volume of each peptide
aptamer in duplicate onto a glass microscope slide, creating
a small microarray. We then probed the microarray with
either of two ﬂuorescently labelled antibodies that recognize
the scaffold protein. After washing, the slides were analysed
using a standard DNA microarray scanner. The signal inten-
sity at each spot obtained with the antibody is proportional
to the amount of peptide aptamer at each feature of the array.
Because we do not normalize the peptide aptamers to a stan-
dard concentration prior to spotting, the signal intensity
should be proportional to the amount of protein expressed in
each of the 384 bacterial cultures. We found that insertions
at loops 1 and 2 were generally well expressed, whereas only
42% of the peptide aptamers with amino-terminal inserts
gave a signal-to-background ratio greater than 3 (Fig. 7 and
Table II).
Discussion
In this study, we aimed to improve the steﬁn A-based STM
scaffold and broaden its versatility. Our analysis of six var-
iants of a steﬁn A-based scaffold indicated structural simi-
larity (Fig. 2). When considering the minimal changes in
SUN, SUM, SUC and SDM, we ﬁnd that the location of the
major inﬂexion point at 219 nm is largely unaffected by each
change, indicating that the proportion of secondary structure
in steﬁn A derivatives is largely unchanged by the amino
acid alterations. This is true even for SQM, the engineered
variant that possesses a combination of all modiﬁcations.
The slight shift in the CD spectrum of STM towards the far
UV compared with all the other variants may be inﬂuenced
by the STM-speciﬁc tryptophan at position 4. We conclude
from these data that SQM is likely to be a suitable and versa-
tile scaffold protein.
The insertion of 10 amino acid long peptides into loop 2
was equally well tolerated by SQM and STM. Only a 17
amino acid insert (A7) caused a deviation from the empty
scaffold spectra in STM. This indicates that A7 may drive a
structural change in the scaffold of STM and that the inser-
tion of inserts longer than 10 amino acids into loop 2 may be
better tolerated by SQM than STM. However, 20 amino acid
long inserts affected the secondary structure of SQM more
than that of STM and decreased the protein yield. This indi-
cates that the two scaffolds are likely to be differentially
affected by different peptide inserts, and thus will present the
same peptides differently. It might also indicate a length
limit of just below 20 amino acids for peptides that are toler-
ated in loop 2 of SQM. We conclude that SQM is able to
present some but not all peptides in loop 2 without adverse
effects on its secondary structure.
By asking whether SQM can present peptide inserts for
interaction with target proteins, we observed that neither
SQM nor STM is able to present thioredoxin-derived BCL-6
POZ domain binders (Chattopadhyay et al., 2006) for posi-
tive interaction in yeast two hybrid assays (data not shown).
Previous attempts to shufﬂe peptides between scaffold
Table I. Presentation of a range of peptides by SQM in the N-terminus,
loop 1 or loop 2: effects on protein yields
Insert Single Double Triple










HA - Myc 4
Myc AU1 HA 7
HA AU1 Myc 2
HAHA AU1 Myc 1
The numbers given correspond to the normalized amounts, in mg, of
puriﬁed peptide aptamer recovered from a notional standard litre of bacterial
culture.
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409proteins as diverse as thioredoxin, staphylococcal nuclease
and GFP have suggested that this can be achieved approxi-
mately one-third of the time (Klevenz et al., 2002), and we
interpret this result to indicate that STM and SQM present
peptides differently than thioredoxin.
Insertion of epitope tags into the N-terminus, loop 1 and/
or loop 2 had varying effects on protein yield and secondary
structure. Most obviously, we observed that N-terminal inser-
tions of short epitope tags were detrimental. Consistent with
this, the analysis of a small-scale microarray of 384 spotted
random peptide aptamers showed a detrimental effect of
insertions at the N-terminus of SQM resulting in lower
protein yields. Analysis of the CD spectra broadly conﬁrmed
these conclusions, showing that epitope peptide insertions at
Fig. 4. Far-UV CD spectra of the SQM scaffold presenting epitope tag peptide inserts. Shown are the far-UV CD spectra of SQM scaffold proteins containing
short epitope tag encoding inserts (AU1, HA, Myc1) in loop 1 (L1) or loop 2 (L2) compared with a reference spectrum of the SQM scaffold (blue) (A), alone
or in combination with N-terminal insertions (B). The data are expressed as mean residual ellipticity (MRE, [u]). Vertical error bars indicate the standard
deviation of the ﬁve STM (red) or seven SQM (blue) CD spectra presented in Fig. 2. The colour version of this ﬁgure is available at PEDS online.
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ary structure. This effect could be due to the insertion at this
site, or the nature of the inserted peptide, which was the HA
or Myc tag in all cases. We return to this question below.
Decreases in protein stability following peptide insertion
could be the result of sequence-speciﬁc effects of the
peptide, or the result of generic effects of peptide insertion
on protein stability, or a combination of the two. When con-
sidering the expression yields of the scaffold proteins pre-
senting various combinations of epitope tag peptides, e.g. the
effects of HA insertion at the amino-terminus, it appears to
be a combination of these. Increased protein yields after
insertion of the AU1 tag at loop 1 and the HA tag at loop 2
might indicate that double insertions may sometimes be ben-
eﬁcial. However, this effect cannot be generalized as replace-
ment of the HA tag with a Myc tag decreased yield almost
15-fold (Table I).
Taken together, the protein expression data show that
SQM is able to present peptides from three sites—the amino
terminus, loop 1 and loop 2. Of these, the new loop 1 site
appears to be most broadly useful, although loop 2 may be
able to present peptides of 10–17 amino acids in length. We
speculate that many (but not all, e.g. A52tandem) longer
inserts may affect the formation of the following b-strand
and hence destabilize the scaffold. Interestingly, most inser-
tions into the amino terminus greatly affect the secondary
structure of the scaffold, rendering use of this site in ﬁrst-
round screens of randomized libraries impractical. We con-
clude that, although peptides can be presented by insertions
at the amino-terminal site, these can also be frequently detri-
mental to the stability of the scaffold conﬁrming our con-
clusions from CD spectra of model peptides. Accordingly,
we do not propose to screen libraries of random peptides
inserted in the amino terminus, but we do expect to be able
to make use of this site to improve peptide aptamers that
interact with the target protein using loop 1 and/or loop 2 by
using a greater surface area and thus create binders with
greater afﬁnity and speciﬁcity.
Speciﬁc recognition of model peptide aptamers
by antibodies
Epitope tags that were presented by SQM on a microarray
were speciﬁcally recognized by antibodies. However, only
weak signals were achieved with anti-AU1 antibody. The
Fig. 5. Immunoprecipitation of SQM presenting the Myc epitope tag. The empty SQM scaffold protein (SQM) or SQM carrying a Myc peptide insert in each
of the three available sites (N, loop 1 or loop 2) were expressed in E.coli. SQM with Myc inserted at the N-terminus also carried an AU1 tag in loop 1 and is
designated SQM-Myc(N)AU1(1). SQM carrying Myc in loop 2 also carries the AU1 epitope insert in loop 1 [SQM-AU1(1)Myc(2)]. The variant carrying the
Myc peptide in loop 1 did not have any other peptide inserts and is designated SQM-Myc(1). Each protein sample was incubated with immobilized anti-Myc
antibody and proteins eluted from these columns were analysed with an antibody recognizing the S-tag present in the amino terminus of all our model peptide
aptamers. Whereas SQM alone was not recruited to the anti-Myc antibody column, all of the other model peptide aptamers were, demonstrating that the Myc
tag is available for interaction regardless of which insertion site is used.
Fig. 6. Fluorescence microarrays of the spotted SQM library on Ni NTA surfaces. Model peptide aptamers with combinations of the three model inserts at each
of the three positions were spotted in quadruplicate, with two peptide aptamers spotted per row. Shown are 10 distinct peptide aptamers whose identity is given
in (D) using the following code: each of the three possible tags (Myc, HA and AU1) is followed by an abbreviation indicating the site at which it is inserted (N:
the amino terminal site; L1: loop 1; L2: loop 2). Thus, Myc(L2) refers to a peptide aptamer with a single insertion of the Myc epitope in loop 2, whereas
Myc(N)Au1(L1)HA(L2) refers to a peptide aptamer with three inserts: a Myc epitope in the amino-terminus, an AU1 epitope in loop 1 and an HA epitope in
loop 2. After spotting, the slides were allowed to dry and were then hybridized with 7 nM anti-Myc-Atto 647N (red, A), 7 nM anti-HA-Atto 647N (red, B)o r
with 28 nM anti-AU1-Atto 550 (green, C). After washing the images were captured using a microarray scanner. The grid layout is summarized in (D). The
colour version of this ﬁgure is available at PEDS online.
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411lower AU1 signal may be due either to the short length of
the AU1 peptide sequence in the epitope loop, with steric
hindrance preventing strong association with the antibody, or
to the inherently low afﬁnity of the anti-AU1 antibody com-
pared with the anti-Myc and the anti-HA antibodies.
Immunoblotting experiments where equal amounts of protein
were analysed and the structure of the scaffold is destroyed
during SDS–PAGE always gave a stronger signal for the
anti-Myc antibody compared with the anti-AU1 antibody
(data not shown). This is clear evidence that the afﬁnity of
the anti-AU1 antibody is lower than the afﬁnity of the
anti-Myc antibody, and this is the most likely explanation for
the lower signal for the AU1 tag in the microarray exper-
iments (Fig. 6). On the basis of these experiments, it can be
concluded that all epitope tags show selective binding to
their corresponding conjugate antibody, though variations in
binding afﬁnity exist. Future experiments will determine
whether the three insertion surfaces can be simultaneously
recognized by three proteins.
In summary, the results described above demonstrate (i)
that the steﬁn A-derived scaffold is amenable to engineering
in multiple locations, with each change alone or in combi-
nation being well tolerated, (ii) that loop 1 of SQM, utilized
here for the ﬁrst time, appears to be a valid site for peptide
insertion, and (iii) that any detrimental effects of the
mutations or of insertions are apparently magniﬁed by inser-
tions in the amino terminus. Therefore, the N-terminal inser-
tion site cannot be used routinely. However, some
N-terminal inserts are tolerated, which will allow us to use
this site to improve the binding afﬁnity and speciﬁcity of
peptide aptamers in SQM-loop 1 and/or loop 2. SQM
appears to be more tolerant to short-sequence insertions into
loop 2 (10 amino acids) than STM but longer inserts (.17–
42 amino acids) often affect the secondary structure. We con-
clude that the SQM scaffold is a valid new SteA-based scaf-
fold protein that should allow the selection of peptide
aptamers with an increased binding afﬁnity and higher target
selectivity than our previous scaffold, STM.
Fig. 7. Microarray comprising 384 random peptide aptamers inserted into loop 1 (top) or loop 2 (centre) or the amino terminus (bottom). Equal volumes of
peptide aptamers puriﬁed from 1.5 ml bacterial cultures and eluted from equal volumes of Ni-agarose beads were spotted in duplicate onto glass slides. The
presence of each peptide aptamer was detected by incubating the whole slide with an antibody that recognizes the scaffold protein (left-hand image). Signal
intensity at each spot (feature) of the array correlates with the amount of protein present and was quantiﬁed using the scanner software (Table II).
Signiﬁcantly, insertions in the amino terminus and to some extent loop 2 appear less well tolerated than insertions into loop 1. Previously characterized peptide
aptamers pep2, pep6, pep9 and pep10m as well as the empty SQM scaffold are given as controls. The colour version of this ﬁgure is available at PEDS online.
Table II. Comparison of signal-to-background ratios as an indicator for
expression levels of 384 peptide aptamers expressed in duplicates and puri-
ﬁed in high throughput format
Signal-to-background ratio Number of spots % total spots
SQM with 6-mer random inserts in loop 1
.3 268 70
2–3 64 17
,25 2 1 4




SQM with 12mer random inserts in N-terminus
.34 0 4 2
2–3 24 25
,23 2 3 3
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Supplementary data are available at PEDS online.
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